Incannex Healthcare Inc.
No SEC Form 4 filings for $IXHL in the last 30 days.
See all $IXHL insider activity →Stonegate Capital Partners updated coverage on Incannex Healthcare Inc. (IXHL), noting active clinical execution of IHL-42X with first-patient dosing underway. The study, enrolling 120 patients, is expected to complete in mid-2027. IXHL has $68.4M in cash, providing 12-month runway. The company's focus is on IHL-42X and its transition to Phase 3.
Incannex Healthcare (Nasdaq: IXHL) said it has started participant screening at first approved sites for its DReAMzz Phase 2 dose confirmation study of IHL-42X in obstructive sleep apnea. The FDA granted IHL-42X Fast Track. Prior Phase 2 results reported up to 83% AHI reduction and improved patient-reported outcomes.
The article says Jeremy Siegel, on CNBC’s “Closing Bell,” expects markets to rise as upcoming earnings show fewer warnings and volatility eases. It also notes oil holding in the low 70s despite no Iran-US deal. It then lists 12 “strong buy” penny stocks under $5, including Keel Infrastructure (KEEL) and Incannex Healthcare (IXHL), citing Citizens’ $10 target for KEEL and a USPTO patent for IXHL.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning IXHL (Incannex Healthcare Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent IXHL coverage spans financial news, technology and market movers.
The trial progression may de‑risk the program and support a higher valuation if enrollment and dose optimization meet expectations.
Active recruitment milestone plus FDA Fast Track designation increases near-term probability of continued clinical progress toward Phase III.
A granted patent strengthens IP defensibility and can improve perceived long-term value of the lead program.
Trial execution update strengthens the path toward planned Phase 3 for IHL-42X.
Rising short interest suggests potential near-term downside pressure or heightened volatility, but market sentiment appears mixed. Without price data or catalysts, directional moves are uncertain; liquidity constraints may amplify moves.
AlphAI scores every news story that mentions IXHL with an AI model for sentiment and relevance, and aggregates insider trades from Incannex Healthcare Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Stonegate Capital Partners updated coverage on Incannex Healthcare Inc. (IXHL), noting active clinical execution of IHL-42X with first-patient dosing underway. The study, enrolling 120 patients, is expected to complete in mid-2027. IXHL has $68.4M in cash, providing 12-month runway. The company's focus is on IHL-42X and its transition to Phase 3.
2 min readIncannex Healthcare (Nasdaq: IXHL) said it has started participant screening at first approved sites for its DReAMzz Phase 2 dose confirmation study of IHL-42X in obstructive sleep apnea. The FDA granted IHL-42X Fast Track. Prior Phase 2 results reported up to 83% AHI reduction and improved patient-reported outcomes.
3 min readThe article says Jeremy Siegel, on CNBC’s “Closing Bell,” expects markets to rise as upcoming earnings show fewer warnings and volatility eases. It also notes oil holding in the low 70s despite no Iran-US deal. It then lists 12 “strong buy” penny stocks under $5, including Keel Infrastructure (KEEL) and Incannex Healthcare (IXHL), citing Citizens’ $10 target for KEEL and a USPTO patent for IXHL.
5 min readBiotech stocks rose Monday as investors reacted to clinical and regulatory updates. Tango Therapeutics (TNGX) jumped 52.97% after initial Phase 1/2 pancreatic cancer data showed 90% 6-month PFS; Alvotech (ALVO) gained 19.77% as the FDA accepted its Entyvio interchangeable biosimilar AVT16; Zevra (ZVRA) rose 13.95% on an Orange Book listing for MIPLYFFA.
7 min readIncannex Healthcare's IXHL short percent of float has risen 82.61% since its last report. The company recently reported that it has 7.21 million shares sold short, which is 10.5% of all regular shares that are available for trading.
3 min readMELBOURNE, Australia and NEW YORK, Aug. 22, 2025 ( GLOBE NEWSWIRE ) -- Incannex Healthcare Inc. ( Nasdaq: IXHL ) ( "Incannex" or the "Company" ) , a clinical-stage biopharmaceutical company developing innovative combination therapies for high-impact conditions, today announced that its Board of ...
2 min readIHL-42X cut AHI by up to 83% in high-dose patients; no serious side effects were reported. Statistically significant sleep, fatigue and oxygen improvements were seen in both dose groups. Get special access to three exclusive "Top 10 Stocks" power lists today, updated daily.
2 min readNEW YORK and MELBOURNE, Australia, June 24, 2025 ( GLOBE NEWSWIRE ) -- Incannex Healthcare Inc. IXHL ( "Incannex" or the "Company" ) , a clinical-stage biopharmaceutical company advancing combination drug therapies for high-impact indications, announces the appointment of Douglas B.
2 min readExpanded platform improves access, scales operations, and advances Incannex's position in next-generation mental health treatment Expanded platform improves access, scales operations, and advances Incannex's position in next-generation mental health treatment ...
3 min readNEW YORK and MELBOURNE, Australia, June 03, 2025 ( GLOBE NEWSWIRE ) -- Incannex Healthcare Inc.
2 min read
